TOP TIERMARKET NEWSWIRE

News & sentiment

SANOFI ADR (SNY) — News & AI sentiment

SANOFI ADR (SNY) news roundup. 2 stories in the last 24 hours, 8 in the past week, 16 over 30 days. Average 24-hour sentiment is 47/100 — neutral (50 is neutral). No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

2

avg sentiment 47/100

7d stories

8

avg sentiment 45.1/100

30d stories

16

avg sentiment 52.6/100

Insider net (90d)

$0

0 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

Latest stories on SNY

Sanofi Pauses Key Bronchiectasis Trial, Raising Questions For SNY Investors

TipRanks38 · neutralgeneral

16h ago

Sanofi Q2 2026 Earnings Preview

Seeking Alpha56 · neutralearnings

18h ago

Malin Writes Down Kymab Contingent Value as Sanofi Halts Amlitelimab

TipRanks32 · bearishgeneral

3d ago

Sanofi Reshapes Executive Committee for Next Strategic Chapter

TipRanks55 · neutralgeneral

3d ago

Eli Lilly and Sanofi-backed Scribe surges in public debut

Seeking Alpha76 · bullishearnings

6d ago

Sanofi is scrapping its once-touted eczema drug in a new CEO pipeline overhaul

Quartz32 · bearishproduct/pr

6d ago

Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO

WSJ34 · bearishgeneral

6d ago

Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO

Morningstar38 · neutralgeneral

6d ago

Sanofi’s Amlitelimab Trial Completion Sets Up a Key Atopic Dermatitis Catalyst

TipRanks63 · neutralproduct/pr

Jul 22

Sanofi’s iGlarLixi Diabetes Trial Nears Readout: What Investors Should Watch

TipRanks56 · neutralproduct/pr

Jul 10

Sanofi: Information concerning the total number of voting rights and shares - June 2026

GlobeNewswire50 · neutralgeneral

Jul 10

Sanofi wins FDA nod for injectable multiple myeloma therapy

Seeking Alpha71 · bullishproduct/pr

Jul 10

Sanofi offers to stop disparaging CSL’s flu vaccine after EU probe

Seeking Alpha48 · neutralgeneral

Jul 8

Sanofi’s Nexviazyme Delivers Positive Phase 3 Results in Infantile-Onset Pompe Disease

TipRanks73 · bullishproduct/pr

Jul 7

Gene editing developer Scribe plots an IPO

Yahoo Top57 · neutralgeneral

Jul 6

R&D Change Underlines Sanofi SA (SNY) Prospects as One of the Best Dividend Stocks to Buy

Yahoo Top63 · neutralproduct/pr

Jul 5

Sanofi Drug for Rare Neuromuscular Disease Hits Goals in Late-Stage Trial

Morningstar73 · bullishproduct/pr

Jun 30

Sanofi's Nexviazyme hits primary goal in Pompe disease study

Seeking Alpha73 · bullishproduct/pr

Jun 30

Deutsche Bank Cuts PT on Sanofi (SNY) – Here’s Why

Yahoo Top56 · neutralanalyst

Jun 27

BofA Expects Positive Investor Reaction to Leadership Update at Sanofi (SNY)

Yahoo Top58 · neutralgeneral

Jun 27

Sanofi Probed by EU Over Flu Vaccine Marketing

Morningstar38 · neutralgeneral

Jun 26

Sanofi investigated by EU over alleged flu vaccine disparagement

Seeking Alpha38 · neutralgeneral

Jun 26

Sanofi: Dupixent Risks Overstated, Valuation Disconnect Creates Opportunity

Seeking Alpha67 · bullishanalyst

Jun 25

Sanofi Secures Multiple June Approvals and New R&D Chief to Bolster Oncology and Neurology Push

TipRanks67 · bullishproduct/pr

Jun 24

Sanofi’s RSV Study in Queensland: What Real-World Uptake Could Mean for Investors

TipRanks56 · neutralgeneral

Jun 23

Open SNY in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →